VistaGen Therapeutics (NASDAQ:VTGN) Posts Quarterly Earnings Results, Beats Expectations By $0.06 EPS

VistaGen Therapeutics (NASDAQ:VTGN) issued its quarterly earnings data on Friday. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.06, FiscalAI reports. The firm had revenue of $1.48 million for the quarter, compared to analysts’ expectations of $0.50 million. VistaGen Therapeutics had a negative net margin of 5,487.01% and a negative return on equity of 133.02%.

VistaGen Therapeutics Trading Up 0.5%

Shares of VTGN traded up $0.00 during mid-day trading on Friday, reaching $0.27. The company had a trading volume of 902,748 shares, compared to its average volume of 2,198,411. VistaGen Therapeutics has a fifty-two week low of $0.20 and a fifty-two week high of $5.14. The firm has a fifty day simple moving average of $0.38 and a 200-day simple moving average of $0.52. The stock has a market cap of $11.88 million, a price-to-earnings ratio of -0.15 and a beta of 0.41.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of VistaGen Therapeutics in a research note on Wednesday, June 3rd. Four analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Reduce” and an average target price of $0.95.

Hedge Funds Weigh In On VistaGen Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of VTGN. Geode Capital Management LLC lifted its position in VistaGen Therapeutics by 18.3% during the fourth quarter. Geode Capital Management LLC now owns 352,836 shares of the company’s stock valued at $234,000 after buying an additional 54,556 shares in the last quarter. Luminus Management LLC purchased a new position in shares of VistaGen Therapeutics in the 4th quarter valued at $232,000. Two Sigma Investments LP lifted its holdings in shares of VistaGen Therapeutics by 223.5% during the 3rd quarter. Two Sigma Investments LP now owns 289,409 shares of the company’s stock valued at $1,027,000 after acquiring an additional 199,958 shares in the last quarter. Millennium Management LLC boosted its position in VistaGen Therapeutics by 853.0% during the 4th quarter. Millennium Management LLC now owns 197,045 shares of the company’s stock worth $130,000 after purchasing an additional 176,369 shares during the period. Finally, Boothbay Fund Management LLC increased its holdings in VistaGen Therapeutics by 10.8% in the 3rd quarter. Boothbay Fund Management LLC now owns 197,024 shares of the company’s stock valued at $699,000 after purchasing an additional 19,166 shares in the last quarter. 78.39% of the stock is owned by institutional investors and hedge funds.

VistaGen Therapeutics Company Profile

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.